9:00 am Chair’s Opening Remarks

9:10 am Late Breaking Abstract: T-cell Therapy for Solid Tumors: Translational Combination Therapies

• Prasad Adusumilli Deputy Chief and Attending, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center

9:30 am Late Breaking Abstract: Co-expression of IL-7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors Without Requiring Preconditioned Lymphodepletion

• Zonghai Li Chief Executive Officer, CARsgen Therapeutics

9:50 am Building a digital backbone to support cell and gene therapies

• Rajesh Singh Managing Director, Deloitte Consulting LLP
• Omkar Kawalekar Manager, Deloitte

10:20 am Live Q&A with Your Expert Speakers

• Prasad Adusumilli Deputy Chief and Attending, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center
• Zonghai Li Chief Executive Officer, CARsgen Therapeutics
• Rajesh Singh Managing Director, Deloitte Consulting LLP

10:35 am Virtual Speed Networking

TRANSLATION

Achieving Clinically Optimal Cell Fitness

11:30 am Mechanisms of Primary Resistance & Tumor Relapse Upon CAR T Cell Therapy in B Cell Lymphoma

• Adrian Bot VP, Translational Medicine, Kite, a Gilead Company

11:50 am Enhancing T Cell Fitness & Expansion

• Chris Heery CMO, Precision BioSciences

12:10 pm Optimizing T-Cell Manufacturing with Next Generation Ancillary Materials

• Ezequiel Zylberberg VP Product Development and Planning, Akron Biotech

12:30 pm Live Q&A with Your Expert Speakers

• Adrian Bot VP, Translational Medicine, Kite, a Gilead Company
• Chris Heery CMO, Precision BioSciences
• Ezequiel Zylberberg VP Product Development and Planning, Akron Biotech

Tech Slam

12:45 pm De-Risk the Fill and Finish Process Through Automation

• Dalip Sethi Manager, Senior Scientist, Terumo BCT

12:55 pm Our Commitment To Providing Excellence To CAR T Cell Therapeutics

• Teng Peng Technical Application Manager, ACROBiosystems

1:05 pm Innovate and Accelerate Cell Therapy Product Development Partnering with GenScript ProBio

• Kenneth Lee Head of Commercial Division, Americas, GenScript ProBio

1:15 pm Refreshment Break

Translational Experience with Allogeneic CAR & TCR Therapy

1:45 pm Non-Gene Edited Approaches for Allogeneic CAR-T Cell Therapies

• Peggy Sotiropoulou Head of Research & Development, Celyad Oncology

2:10 pm Gene-Edited Allogeneic CAR-T Cell Therapies

• Julianne Smith Vice President, Translational Sciences, Cellectis

2:35 pm Genetically Engineered Allogeneic NK Cell lines for Treatment of Cancer & Viral Infections

• Hans Klingemann VP, Research & Development, NantKwest

3:00 pm Refreshment Break

3:10 pm Diversity in CAR-TCR Panel Discussion

• Shon Green Head of Translational R&D, Umoja Biopharma
• Adrienne Farid CDO, Century Therapeutics
• Delfi Krishna Director, Operations, Planning, Strategy, Cell & Gene Therapy, GlaxoSmithKline
• Krishnan Viswanadhan Senior Vice President, Global Cell Therapy Franchise Lead, Bristol-Myers Squibb
• Agnes Yeboah Executive Director, Global Regulatory CMC - Biologics & Cell Therapy, Bristol Myers Squibb

4:10 pm Refreshment Break

Benchmark Clinical Biomarkers to Determine Safety & Efficacy

4:20 pm Development of an Allogeneic, Off-the-Shelf T-cell Immunotherapy & Derivation of a Next-Generation CAR-T Platform

• Blake Aftab VP Preclinical & Translational Science, Atara Biotherapeutics

4:45 pm Using Red Cell TherapeuticsTM to Enhance Antitumor Immune Responses

• Christina Coughlin CMO, Rubius Therapeutics

Strategies to Manage & Prevent Toxicity

5:10 pm CRS Management & Prevention

• Deepu Madduri Assistant Director, Cellular Therapy, The Mount Sinai Hospital

5:35 pm Chair’s Closing Remarks

5:40 pm Post-Conference Networking